An utrophin therapy would benefit all DMD patients and circumvent a potential T-cell mediated immune response that could impair the long-term benefit of prospective dystrophin replacement strategies [32]–[34]. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.